872 Neoadjuvant chemoradiotherapy enhances T cell infiltration in pancreatic ductal adenocarcinoma but high percentage of regulatory T cells associates with poor survival

BackgroundCurrently, diagnosis with pancreatic ductal adenocarcinoma (PDAC) renders an almost intrinsically poor patient prognosis. Despite complete surgical resection and intense neoadjuvant and/or adjuvant treatment the great majority of patients will ultimately relapse and die from the disease. F...

Full description

Saved in:
Bibliographic Details
Published in:Journal for immunotherapy of cancer 2020-11, Vol.8 (Suppl 3), p.A517-A518
Main Authors: Fullerton, Benjamin, Gartrell, Robyn, Enzler, Thomas, Kim, Pan, Fazlollahi, Ladan, Chen, Andrew, Perni, Subha, Weisberg, Stuart, Rizk, Emanuelle, Oh, Eun Jeong, Guo, Xinzheng, Chiuzan, Codruta, Rabadán, Raul, Farber, Donna, Remotti, Helen, Horowitz, David, Saenger, Yvonne
Format: Article
Language:English
Subjects:
Cancer
Chemotherapy
Cytotoxicity
Immunotherapy
Lymphocytes
Medical prognosis
Pancreatic cancer
Patients
Radiation therapy
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundCurrently, diagnosis with pancreatic ductal adenocarcinoma (PDAC) renders an almost intrinsically poor patient prognosis. Despite complete surgical resection and intense neoadjuvant and/or adjuvant treatment the great majority of patients will ultimately relapse and die from the disease. Further, PDAC has been characterized as highly immune resistant. It is speculated that radiation, chemotherapy, or chemoradiation cause the release of tumor antigens and inflammatory cytokines eventually leading to increased immunogenicity of PDAC.MethodsWe used computational quantitative multiplex immune fluorescence (qmIF) (n=31) and the NanoString assay (n=34) to quantitatively analyze the effect of neoadjuvant chemoradiation (CRT) on the tumor immune microenvironment (TIME) of PDAC.ResultsWhen comparing non-treated (NT) to neoadjuvant chemoradiation (CRT) tumors, the proportion of tumor within the overall tissue sample was markedly lower in treated tumors (figure 1; Mann Whitney U, U=25, p
ISSN:2051-1426
DOI:10.1136/jitc-2020-SITC2020.0872